Trade trend analysis
Number of Transactions
Quantity
Weight
Number of Transactions
Quantity
Weight
The above chart presents the market trend analysis for biophore india pharmaceuticals priv from 2025 to 2026.
By examining various dimensions such as transaction quantity, transaction weight, average price,
and transaction frequency, we can gain an intuitive understanding of the company's performance in terms of procurement cycles, business scale, and stability.
As of 2026, the company has completed 4 transactions, with a transaction quantity of 0 and a transaction weight of 16.95.
-
2025
2
0
0.64
-
2026
4
0
16.95
Bill of lading data
<
1/6
>
-
Trade date
2026/06/04
B/L No.
——
-
Suppliers
biophore india pharmaceuticals priv
Buyers
everstpharmaceuticals
-
POLs
——
PODs
dhaka
-
Supply area
India
Purchas area
Bangladesh
-
Weight
0.6kg
Amount
21000
-
Hs code
29349990
Product tags
tipiracil
-
Product description
TIPIRACIL HCL
Expand
-
Trade date
2026/06/04
B/L No.
——
-
Suppliers
biophore india pharmaceuticals priv
Buyers
everstpharmaceuticals
-
POLs
——
PODs
dhaka
-
Supply area
India
Purchas area
Bangladesh
-
Weight
1.35kg
Amount
40500
-
Hs code
29349990
Product tags
trifluridine
-
Product description
TRIFLURIDINE IH
Expand
-
Trade date
2026/03/03
B/L No.
——
-
Suppliers
biophore india pharmaceuticals priv
Buyers
albion laboratories inc.
-
POLs
——
PODs
dhaka
-
Supply area
India
Purchas area
Bangladesh
-
Weight
10kg
Amount
3800
-
Hs code
29333990
Product tags
dmf,bilastine
-
Product description
BILASTINE (USDMF)
Expand
-
Trade date
2026/02/19
B/L No.
——
-
Suppliers
biophore india pharmaceuticals priv
Buyers
albion specialized pharma limited
-
POLs
——
PODs
dhaka
-
Supply area
India
Purchas area
Bangladesh
-
Weight
5kg
Amount
1925
-
Hs code
29333990
Product tags
dmf,bilastine
-
Product description
BILASTINE (USDMF)
Expand
-
Trade date
2025/08/26
B/L No.
——
-
Suppliers
biophore india pharmaceuticals priv
Buyers
radiant pharmaceuticals ltd. change
-
POLs
——
PODs
dhaka
-
Supply area
India
Purchas area
Bangladesh
-
Weight
0.14kg
Amount
3530.8
-
Hs code
29339900
Product tags
cariprazine
-
Product description
CARIPRAZINE HCL
Expand
-
Trade date
2025/05/15
B/L No.
——
-
Suppliers
biophore india pharmaceuticals priv
Buyers
renata plc. changed from renata
-
POLs
——
PODs
dhaka
-
Supply area
India
Purchas area
Bangladesh
-
Weight
0.5kg
Amount
10000
-
Hs code
29349990
Product tags
meglumine,mat,tafamidis
-
Product description
PH. RAW. MAT=TAFAMIDIS MEGLUMINE
Expand
+View All
Products
Total 6
-
dmf
2
50%
>
-
bilastine
2
50%
>
-
cariprazine
1
25%
>
-
meglumine
1
25%
>
-
mat
1
25%
>
+View All
Hscode rank
Total 0
-
HS 29333990
2
50%
>
-
HS 29339900
1
25%
>
-
HS 29349990
1
25%
>
biophore india pharmaceuticals priv is india Supplier,
and primarily engages in the import and export business of products such as dmf,bilastine,cariprazine.
According to the 52wmb.com global trade database, as of 2026-06-04, the company has completed 6 international trades,
The core products include HS29333990,HS29339900,HS29349990 etc,
and its main trading partners are everstpharmaceuticals,albion laboratories inc.,radiant pharmaceuticals ltd. change.
These trade data are sourced from various countries' customs and public channels, and have undergone standardization and structuring processing.
They can reflect the import and export trends and main market layout of the enterprise, and are suitable for market trend analysis, competitor research, port transportation planning, supply chain optimization, and international customer development.
They provide reliable support for cross-border trade decision-making.
The trade data displayed on biophore india pharmaceuticals priv is sourced from the 52wmb.com global trade database. It is based on legal records from customs and related public channels of various countries, and has been formatted and organized for user query and analysis.
We maintain compliance with the source and processing of data to ensure the objectivity of information, but due to the dynamic changes in international trade activities, some data may be delayed or changed.